Skip to main content
OpenTrials
Completed

NCT Number: NCT07177404

Choices and Experiences Around Closed-loop Therapy in Type 1 Diabetes

Type 1 diabetes requires a lot of work to try to keep glucose levels in the target range. Hybrid closed- loop, also known as artificial pancreas, takes glucose readings from a sensor (continuous glucose monitor) and uses an algorithm to tell an insulin pump how much insulin to deliver. Hybrid closed-loop has currently been rolled out to many people with type 1 diabetes in England. We are keen to develop a deeper understanding of the perspective of people living with type 1 diabetes who have choices about which hybrid closed-loop systems fit their needs.

The main purpose of this study is to explore the choices and experiences of people living with type 1 diabetes regarding closed-loop therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabete Mellitus Autoimmune Diseases Diabetes Mellitus Diabetes Mellitus, Type 1 Endocrine System Diseases Glucose Metabolism Disorders Immune System Diseases Metabolic Diseases Nutritional and Metabolic Diseases Type 1 Diabetes Mellitus

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospitals of Derby and Burton

Derby, United Kingdom

About this study

This is a cross-sectional online survey study, which involves people with type 1 diabetes who use closed-loop, wait to start closed-loop or considering closed-loop.

The primary objective of the study is to explore the factors driving the choices of people living with type 1 diabetes regarding closed-loop therapy.

The secondary objectives of the study are:

  • To understand what treatment satisfaction with closed-loop therapy means to people living with type 1 diabetes
  • To understand what additional support is needed for people with type 1 diabetes using closed-loop therapy

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: ≥18 years (no upper age limit)
  • Type 1 diabetes (any duration)
  • People who use closed-loop therapy or wait to start closed-loop therapy or considering closed-loop therapy in the future
  • Ability to give informed consent

Exclusion criteria

  • Any other type of diabetes apart from type 1 diabetes

Treatment and study plan

Primary outcomes

  1. Ranking of factors influencing the choice of closed-loop therapy among people with type 1 diabetes

    Time frame: Day 1

Secondary outcomes

  1. Ranking of factors contributing to treatment satisfaction with closed-loop therapy

    Time frame: Day 1

  2. Distribution of responses to 5-point Likert scale questions assessing factors contributing to treatment satisfaction with closed-loop therapy

    Time frame: Day 1

  3. Distribution of responses to 5-point Likert scale questions assessing the support needs of people using closed-loop therapy

    Time frame: Day 1

  4. Associations of demographics and reported glucose levels with factors influencing the choice of closed-loop therapy

    Time frame: Day 1

  5. Associations of demographics and reported glucose levels with factors contributing to treatment satisfaction with closed-loop therapy

    Time frame: Day 1

  6. Associations of demographics and reported glucose levels with support needs related to closed-loop therapy

    Time frame: Day 1

Sponsors and collaborators

Lead sponsor

University of Nottingham

Other

Registry information

Official study title

Surveying Experiences and Lifestyle Effects in Choosing Technology and Hybrid Closed Loop in Type 1 Diabetes

Acronym: SELECT HCL

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 17, 2025
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.